Lupus systémique : quels patients et quelle prise en charge en Centre Hospitalier Général ? (notice n° 1578859)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04881cam a2200373 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20251228045551.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Lecapitaine, Anne-Lise |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Lupus systémique : quels patients et quelle prise en charge en Centre Hospitalier Général ? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2017.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 25 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Objectifs : Le lupus systémique est une maladie nécessitant un suivi régulier. Les études de la littérature concernant principalement les Centres Hospitaliers Universitaires (CHU), nous avons souhaité décrire une population de patients lupiques en Centre Hospitalier Général (CHG), avec les modalités de suivi et de traitement, dans une démarche d’évaluation des pratiques professionnelles. Méthodes : Nous avons mené une étude descriptive, rétrospective, des patients lupiques suivis entre mars 2013 et mars 2015 au Centre hospitalier intercommunal Robert Ballanger d’Aulnay-sous-Bois, en Seine-Saint-Denis (France). Résultats : Les atteintes d’organes présentées par les 39 patients inclus se répartissaient ainsi : 77 % des patients avaient une atteinte articulaire, 67 % cutanée, 44 % hématologique, 26 % des séreuses, 13 % rénale, 13 % neuropsychiatrique, 8 % digestive et 2 % myocardique. Sur le plan thérapeutique, 35 patients ont reçu un traitement de fond par hydroxychloroquine et 12 un immunosuppresseur ou une biothérapie. Les patients ont été vus trois à quatre fois par an en consultation ; 19 patients ont été hospitalisés au moins une fois en hospitalisation traditionnelle, et 27 au moins une fois en hôpital de jour. Un avis auprès d’un confrère en Centre Hospitalier Universitaire (CHU) était demandé pour six patients, avec un transfert de suivi pour une seule patiente. Conclusion : Nos patients présentaient des atteintes similaires aux grandes séries, en dehors d’une moindre proportion d’atteinte rénale. Les attitudes thérapeutiques étaient adaptées aux recommandations, avec des interactions fréquentes avec le CHU. Des axes d’amélioration ont été identifiés : renforcer le dépistage des complications cardiovasculaires et les vaccinations, et espacer la surveillance ophtalmologique sous hydroxychloroquine. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Systemic lupus erythematosus: a French general hospital experience Objectives : Systemic lupus erythematosus (SLE) is a disease requiring long-term follow-up. Most studies published in the literature concerned teaching hospitals. We wanted to study a population of SLE patients, their follow-up and therapeutic modalities in a general hospital in order to evaluate professional practices. Methods : We performed a descriptive and retrospective study with SLE patients followed at Centre Hospitalier Intercommunal Robert Ballanger in Aulnay sous Bois (Seine Saint-Denis) between March 2013 and March 2015. Results : Thirty-nine patients were included with various forms of the disease: 77% presented arthritis, 67% had skin involvement, 44% had haematological disorders, 26% had serosal involvement, 13% had kidney involvement, 13% had neuropsychiatric disorders, 8% had digestive tract involvement and 2% had myocarditis. Thirty-five patients were treated with hydroxychloroquine and 12 were treated with immunosuppressive or biotherapy. Patients were seen 3 or 4 times a year as outpatients; 19 were hospitalized at least once in conventional wards and 27 were admitted at least once to a day hospital. Advice from a teaching hospital colleague was required for 6 patients, but only one patient was permanently followed in another hospital. Conclusion : Our patients had similar clinical features to those reported in large series, except for a lower prevalence of renal injuries. Therapeutic management was in accordance with guidelines, with frequent discussion with teaching hospitals. We identified measures to improve our follow-up : more cardiovascular prevention, more vaccinations and adjustment of hydroxychloroquine monitoring. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ėvaluation des pratiques professionnelles |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | évaluation des soins de santé par des pairs |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hôpital général |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lupus erythémateux disséminé (LED) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | maladies auto-immunes |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | systémique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Autoimmune diseases |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | general |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | health care |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Hospital |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lupus erythematosus |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | peer review |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | systemic |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bakir, Redouane |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Delassus, Jean-Luc |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gros, Hélène |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bouldouyre, Marie-Anne |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Santé Publique | 29 | 1 | 2017-03-06 | p. 47-55 | 0995-3914 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-sante-publique-2017-1-page-47?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-sante-publique-2017-1-page-47?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux